Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 101 related to Chu: Differential effects of metformin and troglitazone on cardiovascular risk factors in.... (0.15 sec) 

Differential effects of metformin and troglitazone on cardiovascular risk factors in …

- diabetesjournals.org
NV Chu, APS Kong, DD Kim, D Armstrong, S Baxi, … - Diabetes Care, 2002 - Am Diabetes Assoc
RESEARCH DESIGN AND METHODS—We compared the addition of metformin or troglitazone
therapy on CVRF in 22 subjects with type 2 diabetes who remained in poor glycemic control
(with HbA 1c >8.5%) while taking glyburide 10 mg twice daily. Subjects were initially ...
Cited by 154 - Related articles - BL Direct - All 8 versions

[PDF] Differential effects of metformin and troglitazone on cardiovascular risk factors in …


M Caulfield, SR Mudaliar, R Reitz, RR Henry, PD … - Diabetes Care, 2002 - Am Diabetes Assoc
OBJECTIVE — Traditional cardiovascular risk factors (CVRF) only partly explain the exces- sive
risk of cardiovascular disease in patients with type 2 diabetes. There is now an increasing appreciation
for many novel CVRF that occur largely as a result of insulin resistance and hyper- ...
Cited by 1 - Related articles

The effects of high-and medium-dose metformin therapy on cardiovascular risk …


PJ Grant - Diabetes Care, 1996 - Am Diabetes Assoc
OBJECTIVE: To study the dose response to metformin in type II diabetic patients. RESEARCH
DESIGN AND METHODS: Type II diabetic patients with a BMI > 25 were treated with 3,000
mg/day (n = 27), 1,500 mg/day (n = 25), or placebo (n = 23) for 6 months. Venous blood ...
Cited by 112 - Related articles - BL Direct - All 5 versions

Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled …

- kau.edu.sa [PDF] 
DH Akbar - Endocrine, 2003 - Springer
Received November 4, 2002; Revised December 10, 2002; Accepted Decem- ber 10, 2002.
Author to whom all correspondence and reprint requests should be addressed: Dr. Daad H.
Akbar, Jeddah 21415, PO Box 18298, Kingdom of Saudi Arabia. E-mail: daadakb@yahoo. ...
Cited by 35 - Related articles - BL Direct - All 13 versions

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, …


DK Nagi, JS Yudkin - Diabetes Care, 1993 - Am Diabetes Assoc
OBJECTIVE--To investigate the effects of metformin on glycemic control, insulin resistance, and
risk factors for cardiovascular disease in NIDDM subjects from two ethnic groups (Caucasian
and Asian) with different risks of cardiovascular disease. RESEARCH DESIGN AND ...
Cited by 252 - Related articles - BL Direct - All 5 versions

Effects of short-term treatment with metformin on markers of endothelial function …


J Jager, A Kooy, PH Lehert, D Bets, MG … - Journal of internal …, 2005 - interscience.wiley.com
It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ...
Cited by 84 - Related articles - BL Direct - All 6 versions

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the …

- diabetesjournals.org
N Satoh, Y Ogawa, T Usui, T Tagami, S Kono, H … - Diabetes Care, 2003 - Am Diabetes Assoc
RESEARCH DESIGN AND METHODS—A total of 136 Japanese type 2 diabetic patients were
included and divided into two groups: the pioglitazone-treated group (30 mg daily for 3
months) (n = 70) and the untreated control group (n = 66). The changes in glycolipid ...
Cited by 254 - Related articles - BL Direct - All 5 versions

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular …

- ahajournals.org
SM Haffner, AS Greenberg, WM Weston, H Chen, K … - Circulation, 2002 - Am Heart Assoc
Background— Markers of systemic inflammation (eg, C-reactive protein [CRP] and
interleukin-6 [IL-6]) have been proposed to be "nontraditional" risk factors for cardiovascular
disease in patients with type 2 diabetes mellitus. Matrix metalloproteinase-9 (MMP-9) has ...
Cited by 837 - Related articles - BL Direct - All 9 versions

Rosiglitazone improves insulin sensitivity and lowers blood pressure in …


A Raji, EW Seely, SA Bekins, GH Williams, DC … - Diabetes care, 2003 - Am Diabetes Assoc
RESULTS—There was no change in fasting plasma glucose (83 ± 2 vs. 82 ± 2 mg/dl, P =
0.60), but fasting insulin decreased (16.1 ± 1.4 vs. 12.5 ± 0.9 μU/ml, P < 0.01). Total glucose
disposal during the clamp increased (5.0 ± 0.4 vs. 5.9 ± 0.5 mg · kg −1 · min −1 , P < ...
Cited by 233 - Related articles - BL Direct - All 8 versions

Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double- …


S Fullert, F Schneider, E Haak, H Rau, K … - Journal of Clinical …, 2002 - Endocrine Soc
Hypertension is often associated with insulin resistance, dyslipidemia and obesity, which indicate
a prediabetic state and increased risk of cardiovascular disease. Pioglitazone treatment of patients
with type 2 diabetes reduces insulin resistance and improves lipid profiles. The present ...
Cited by 118 - Related articles - All 7 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google